Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$114.65M-33.36%Company Profile
- CEO
- Jay S. Sugarman
- Sector
- Real Estate
- Industry
- REIT - Diversified
- Employees
- 118
- Beta
- 1.28
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 0.62
Financials
Revenue
$114.65M-33.4%Net Income
$30.16M+47.0%EBITDA
$91.00M-6.3%Free Cash Flow
$26.04MEPS (diluted)
$0.42+55.6%Shares Outstanding (diluted)
71.58M-7.1%Operating Expenses
$14.34MCash & Debt
$15.92MReturn of Capital
$41.84MRevenue by Segment (annual)
$209.66MDividend per Share
$0.78Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $385.55M | $114.47M | $1.60 |
| 2024 | $365.69M | $105.76M | $1.48 |
| 2023 | $352.58M | $-54.97M | $-0.82 |
| 2022 | $158.05M | $-197.27M | $-128.31 |
| 2021 | $308.63M | $16.57M | $1.44 |
| 2020 | $530.95M | $-30.85M | $-2.55 |
| 2019 | $479.50M | $324.04M | $28.19 |
| 2018 | $798.12M | $-32.26M | $-0.47 |
| 2017 | $679.20M | $83.63M | $1.18 |
| 2016 | $455.19M | $-9.99M | $-0.14 |
| 2015 | $496.03M | $-96.25M | $-1.13 |
| 2014 | $462.03M | $-73.47M | $-0.86 |
| 2013 | $390.80M | $-112.00M | $-1.32 |
| 2012 | $400.40M | $-239.90M | $-2.86 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.35
- Implied price
- $42.23
- Return from $7.63
- 40.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $20.99 — today's price is already 63.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 17.8% | 23.2% | 27.8% | 31.8% | 35.3% |
| 3.0% | 23.8% | 29.5% | 34.3% | 38.5% | 42.2% |
| 8.0% | 29.8% | 35.8% | 40.8% | 45.2% | 49.1% |
| 13.0% | 35.8% | 42.0% | 47.3% | 51.9% | 56.0% |
| 18.0% | 41.9% | 48.3% | 53.8% | 58.7% | 63.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
150+650.00%Social Signal Score
Mentions (4)
- Newsbusinesswire.com·6h ago·Neutral
ProShares GENIUS Money Market ETF (IQMM) Wins Product Innovation Award at the 2026 Financial Times Asset Management STAR Awards North America BETHESDA, Md.--(BUSINESS WIRE)--ProShares' IQMM wins Product Innovation and New Product Development award at 2026 Financial Times Asset Management STAR Awards North America.
View source ↗ - Newsbusinesswire.com·10h ago·Neutral
… Experience: a Space Where Artificial Intelligence and Immersive Technologies Bring Multisensory Brand Experiences to Life TURIN, Italy--(BUSINESS WIRE)--Reply [EXM, STAR: REY] introduces Reply Immersive Experience, a multisensory smart room that combines artificial intelligence and immersive technologies to create environments where audiences can explore products, interact with digital scenarios and take part in stories that unfold in the space around them. Images, sound, lighting and settings …
View source ↗ - Newsbusinesswire.com·7d ago·Neutral
Reply Introduces Symbiosis: an AI-Driven Operating Model to Align Business Priorities and AI-Accelerated Delivery TURIN, Italy--(BUSINESS WIRE)--Reply [EXM, STAR: REY] introduces Symbiosis, an AI-driven operating model designed for enterprises integrating generative AI and agentic systems into their operating processes. Supported by a dedicated platform, Symbiosis connects strategy, portfolio management and execution, helping organisations align priorities and investment decisions with measurabl…
View source ↗ - Newsbusinesswire.com·14d ago·Negative
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead's upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG …
View source ↗
Earnings
Typical surprise +194.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 2$0.35 vs $-0.15beat
- Mon, May 1$0.53 vs $-0.15beat
- Tue, Feb 21$-0.92 vs $-0.05miss
- Thu, Nov 3$0.33 vs $0.04beat
- Thu, Aug 4$-0.42 vs $-1.01beat
- Wed, May 4$7.79 vs $5.08beat
Estimates and results for STAR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STAR officers and directors.
- Bought
- —
- Sold
- $46k
1 trade
2 trades
- Asnas Brettbought
- Rosenblum Garettsold
- Rosenblum Garettsold
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Greg Gianfortehouse · MT00 · disclosed Jan 23, 2019 (33d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.